Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps as a potential treatment for age-related conditions, today announced the commencement of several significant milestones. These events underscore its commitment to advancing innovative treatments to mitigate the effects of aging and the continuation of its groundbreaking work.
https://www.morningstar.com/news/globe-newswire/9145781/telomir-pharmaceuticals-announces-two-pivotal-milestones-for-lead-product-candidate-telomir-1
https://www.morningstar.com/news/globe-newswire/9145781/telomir-pharmaceuticals-announces-two-pivotal-milestones-for-lead-product-candidate-telomir-1
No comments:
Post a Comment